Abstract: A photodynamic therapy apparatus for local targeting in cancer treatment capable of treating various types of cancers or tumors. An endoscope is placed in the center of an end portion of a probe used in photodynamic therapy and a plurality of optical fibers are arranged along the edge thereof, so that a lesion site is irradiated with a plurality of lights while the plurality of optical fibers of the probe receive lights from individual light sources, respectively, to perform light irradiation individually. An apparatus is disclosed, wherein unnecessary damage to normal tissues is minimized by controlling light irradiation regions, for instance, by defining light irradiation regions encompassing a lesion site from an image provided in real time through an endoscope disposed at an end portion of a probe and allowing only individual light sources irradiating the defined light irradiation regions to emit lights to achieve local light irradiation.

Abstract: Modifications to interleukin-2 alpha receptors are disclosed. Interleukin-2 analogs with increased binding affinity for interleukin-2 beta receptors are disclosed.

Abstract: Disclosed is a method for extracting high-purity polydeoxyribonucleotide (PDRN) from salmon testes, including 1) separating semen and immature testicular regions from the testes of a salmonid fish, 2) gently grinding the immature testicular regions, followed by dilution with an artificial seminal plasma, 3) treating the dilution with a predetermined concentration of human chorionic gonadotropin (hCG) to induce artificial sexual maturation of the testicular cells to sperm, 4) centrifuging the testicular dilution after the passage of a predetermined time from the hCG treatment and collecting potentially motile sperm, and 5) extracting PDRN from the collected sperm. The method enables the production of raw materials for PDRN with a 100- to 200-fold higher purity from 20 mL (a maximum of 50 mL) of sperm (semen) collected at one time from a salmonid fish. In addition, the method enables the extraction of PDNR in high yield in a cost-effective and economically viable manner.

Abstract: Provided is a composition comprising 2,4,6-trihydroxyacetophenone (THA) as an active ingredient, and a method for preventing, alleviating or treating breast cancer using the composition by inhibiting the activity of polo-like kinase 1 (PlK1).

Abstract: The present invention relates to a crystalline form of a phenyl carbamate derivative compound and a use thereof, and more particularly, to a more thermodynamically stable crystal, i.e., a Pattern 1 crystalline form, and a preparation method thereof. Amorphous and crystalline forms were prepared using various solvents, and among these, a thermodynamically stable Pattern 1 crystalline form and a pharmaceutical use of this crystalline form are provided.

Abstract: This disclosure provides a method of preventing, alleviating or treating a condition (i.e., neutropenia) in a subject in need thereof, the condition characterized by compromised white blood cell production in the subject. The method includes administering to the subject a therapeutically effective amount of a protein complex on the same day as a chemotherapy regimen, wherein the protein complex is a modified human granulocyte-colony stimulating factor (hG-CSF) covalently linked to an immunoglobulin Fc region via a non-peptidyl polymer. The non-peptidyl polymer is site-specifically linked to an N-terminus of the immunoglobulin Fc region, and the modified hG-CSF comprises substitutions in at least one of Cys17 and Pro65.

Abstract: Disclosed is a test strip for detecting microalbumin in urine, and more particularly a test strip for detecting microalbumin in urine that contains a synthetic albumin indicator, a buffer solution, a surfactant and a polymer (sensitizer) and thus exhibits high sensitivity. The albumin detection test strip has accuracy sufficient to enable clear observation of color change from colorless to blue through the albumin indicator, and improves the detection limit (increases sensitivity) to thereby enable detection of microalbuminuria at a concentration of 20 mg/L or less. The albumin test detection strip contains a surfactant and a polymer in addition to a synthetic albumin indicator, thereby incorporating separate first and second processes into a single process and having effects of reducing costs, improving processing convenience, and increasing solubility and miscibility.

Abstract: New therapeutic uses of a triple agonistic long-acting conjugate or a triple and a farnesoid X receptor (FXR) agonist, or a combination further containing an acetyl-CoA carboxylase (ACC) inhibitor are disclosed. The triple agonistic long-acting conjugate or a triple and a farnesoid X receptor (FXR) agonist, or a combination further containing an acetyl-CoA carboxylase (ACC) inhibitor, may be for preventing or treating a liver disease.

Abstract: New therapeutic uses of a glucagon derivative or a conjugate thereof are disclosed. The glucagon derivative or a conjugate thereof is represented by the following formula: Y-X2-QGTF-X7-SDYSKY-X14-D-X16-X17-R-X19-X20-X21-FVQWLMNT-X30 (General Formula 1, SEQ ID NO: 46), and is effective in preventing or treating a liver disease. Therefore, the glucagon derivative or a conjugate thereof, or a pharmaceutical composition containing it as an active ingredient may be for preventing or treating a liver disease.

Abstract: Provided are a pharmaceutical composition including a long-acting conjugate of a triple agonist as an active ingredient and a method of treating obesity and/or a non-alcoholic fatty liver disease using the same. The pharmaceutical composition including the long-acting conjugate of the triple agonist of the present invention may be stably applied to treatment of obesity and/or a non-alcoholic fatty liver disease without side effects according to therapeutic effects on obesity and/or the non-alcoholic fatty liver disease.

Abstract: The present application relates to a novel, cost-saving and efficient process for preparing 4-(2,2,3,3-tetrafluoropropyl)morpholine which serves as an intermediate for production of medicaments and for production of medicaments for treatment and/or prophylaxis of cardiovascular disorders.

Abstract: A liquid formulation of a long-acting conjugate of glucagon, GLP-1, and GIP trigonal agonist, and a method for preparing the liquid formulation are disclosed. The liquid formulation contains 18 nmol/mL to 920 nmol/mL of a long-acting conjugate, a buffering agent in an amount for maintaining the pH of the liquid formulation in the range of 5.0 to 7.0, and 0.5% (w/v) to 10% (w/v) of a sugar alcohol, saccharide, or a combination thereof.

Abstract: A liquid formulation of a long-acting conjugate of GLP-2 and a method for preparing the liquid formulation are disclosed. The liquid formulation contains 18 nmol/mL to 18,630 nmol/mL of a long-acting conjugate, a stabilizer, and a buffering agent in an amount for maintaining the pH of the liquid formulation in the range of 4.5 to 6.5.

Abstract: The present invention relates to an insulin analog conjugate and use thereof.

Abstract: Provided in the present disclosure is a composition comprising hydroquinone or a derivative thereof as an active ingredient, and characterized in that the hydroquinone or the derivative thereof is stabilized by means of poloxamer. The composition of the present disclosure increases the soluble concentration of the hydroquinone or the derivative thereof, can have high melt stability without precipitation even at high concentration in water, can enhance storage stability by preventing oxidation reaction to external stimulations such as heat, oxygen and light, can prevent discoloration, and thus has reduced toxicity induced by an oxidation product of the hydroquinone and can reduce inflammatory response. Also, the composition of the present disclosure can enhance whitening efficacy by enhancing the skin permeability of the hydroquinone or the derivative thereof by means of micelles, and thus is useful for a whitening activity having hydroquinone or a derivative thereof as an active ingredient.

Abstract: The present invention relates to changes in interleukin-2 alpha receptors and interleukin-2 analogs with increased binding affinity for interleukin-2 beta receptors.

Abstract: Provided is a brightening use of a composition including sodium pyruvate and one or more selected from the group consisting of urea and hydroxyethyl urea. Since the composition exhibits a synergistic brightening effect, even when a low concentration of sodium pyruvate is included, a brightening effect at the same level as when a high concentration of sodium pyruvate is used can be obtained. Therefore, the composition can be effectively applied in cosmetics, medicines, external preparations, and the like.

Abstract: The present invention relates to a pharmaceutical composition comprising, as an active ingredient, a fusion protein in which a tissue-penetrating peptide is fused to an anti-vascular endothelial growth factor agent, methods of treating eye diseases with the pharmaceutical composition, and a method for preparing an anti-VEGF agent with an improved efficacy and ability to overcome resistance.

Abstract: Provided are a composite formulation including sitagliptin and dapagliflozin and a method of preparing the same.

Abstract: Provided are a pharmaceutical composite formulation and a method of preparing the same, the pharmaceutical composite formulation including: a first layer containing, as an active ingredient, a proton pump inhibitor or a pharmaceutically acceptable salt thereof and a lubricant, and a second layer containing, as an active ingredient, an antacid selected from magnesium hydroxide, magnesium oxide, and a mixture thereof.